AR041645A1 - Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo - Google Patents
Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodoInfo
- Publication number
- AR041645A1 AR041645A1 ARP030103776A ARP030103776A AR041645A1 AR 041645 A1 AR041645 A1 AR 041645A1 AR P030103776 A ARP030103776 A AR P030103776A AR P030103776 A ARP030103776 A AR P030103776A AR 041645 A1 AR041645 A1 AR 041645A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- concentration
- free
- critical
- grow
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/95—Protein-free medium and culture conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Método de obtención de células de mamífero adaptadas a crecer en medio libre de suero y proteínas, el procedimiento incluye un proceso en dos etapas de adaptación para crecer en esa condición. Se revela la existencia de un intervalo crítico de concentración de proteína en el cual las células deben crecer para ganar la capacidad de sobrevivir en medio libre de proteínas, una vez que las células hayan crecido en las concentraciones críticas del intervalo, las disminuciones subsiguientes de la concentración no afectan la viabilidad ni el tiempo de doblaje celular. El intervalo crítico de la concentración de la proteína es específico para cada línea celular. Líneas celulares de mamíferos que crecen establemente en condiciones de medio libre de suero y proteínas por al menos 40 generaciones. Adicionalmente, los clones revelados, expresan un producto recombinante. Los clones expresan los anticuerpos anti receptor de EGF hR3, el anti CD6 T1hT humanizados y el anticuerpo quimérico anti CD3 T3Q, además de los fragmentos de dichos anticuerpos. Reivindicación 1: Un método para obtener una línea celular de mamífero adaptada a crecer en medio libre de suero y proteína que comprende dos etapas: I) Una primera etapa en la cual a partir de una línea con una viabilidad celular entre 80 y 100%, las células se crecen sucesivamente en medio de cultivo con concentraciones decrecientes de proteína hasta alcanzarse una concentración crítica de proteína donde la viabilidad cae a 0%; II) Una segunda etapa donde una vez determinada la concentración crítica, se busca la concentración precedente, donde aún existe crecimiento celular considerada como concentración pre-crítica, y a partir de la misma se disminuye lentamente dicha concentración de proteína hasta que las células recuperen la viabilidad y el tiempo de doblaje original.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20020239A CU23097A1 (es) | 2002-10-23 | 2002-10-23 | Método para la obtención de líneas celulares en medio libre de proteína y líneas celulares obtenidas por este método |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041645A1 true AR041645A1 (es) | 2005-05-26 |
Family
ID=40134843
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103776A AR041645A1 (es) | 2002-10-23 | 2003-10-16 | Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20060036082A1 (es) |
| EP (2) | EP2363418B1 (es) |
| JP (1) | JP4674087B2 (es) |
| KR (1) | KR101186048B1 (es) |
| CN (1) | CN1714147B (es) |
| AR (1) | AR041645A1 (es) |
| AT (1) | ATE502103T1 (es) |
| AU (1) | AU2003273727B2 (es) |
| BR (1) | BR0315565B1 (es) |
| CA (1) | CA2503315C (es) |
| CU (1) | CU23097A1 (es) |
| DE (1) | DE60336415D1 (es) |
| DK (1) | DK1564285T3 (es) |
| EA (1) | EA007465B1 (es) |
| EC (1) | ECSP055740A (es) |
| ES (2) | ES2360049T3 (es) |
| GE (1) | GEP20084444B (es) |
| HR (1) | HRP20050760A2 (es) |
| LT (1) | LT5354B (es) |
| LV (1) | LV13361B (es) |
| MY (1) | MY144088A (es) |
| NZ (1) | NZ540171A (es) |
| PE (1) | PE20040552A1 (es) |
| PT (1) | PT1564285E (es) |
| TN (1) | TNSN05116A1 (es) |
| UY (1) | UY28037A1 (es) |
| WO (1) | WO2004038010A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104651314B (zh) * | 2015-02-14 | 2018-06-19 | 百泰生物药业有限公司 | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 |
| CN104673754B (zh) * | 2015-02-14 | 2018-03-02 | 百泰生物药业有限公司 | 重组骨髓瘤细胞克隆的筛选方法及由此获得的抗体分子 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3694263A (en) * | 1970-10-23 | 1972-09-26 | Joseph J Korn Sr | Swimming pool cleaning methods and apparatus therefor |
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US3886616A (en) * | 1972-12-06 | 1975-06-03 | Fay A Hayes | Hand propelled swimming pool cleaner |
| US4275474A (en) * | 1979-04-30 | 1981-06-30 | Woodard Randle C | Vacuum head for swimming pool cleaning system |
| US4240174A (en) * | 1979-07-30 | 1980-12-23 | Scott Jeffrey L | Self-contained mobile pool cleaning apparatus |
| US4430214A (en) * | 1982-09-15 | 1984-02-07 | Baker Marvin E | Strainer mill for swimming pool pump intake |
| AU2986484A (en) * | 1983-06-27 | 1985-01-03 | Monash University | Leptospira strains grown in protein free medium |
| US4558479A (en) * | 1984-01-26 | 1985-12-17 | Alopex Industries, Inc. | Pool cleaner |
| US4683599A (en) * | 1984-03-30 | 1987-08-04 | Fahet Nv | Automatic pool cleaner fitting |
| US4581075A (en) * | 1985-03-15 | 1986-04-08 | Maxi-Sweep, Inc. | Self-propelled water borne pool cleaner |
| AU6291090A (en) | 1989-09-29 | 1991-04-28 | Atomic Energy Of Canada Limited | Infrared-based gas detector |
| JP2696001B2 (ja) | 1991-04-15 | 1998-01-14 | 財団法人化学及血清療法研究所 | 組換え蛋白質産生用培地 |
| EP0531562A1 (de) | 1991-09-11 | 1993-03-17 | Doerr, Hans-Wilhelm, Prof. Dr. med. | Kultivierung von Säugetierzellen |
| DK0784684T3 (da) * | 1994-09-16 | 2007-12-17 | Cancer Res Inst Of Contra Cost | Rekombinante peptider afledt af Mc3 anti BA46 antistoffet, fremgangsmåder til anvendelse deraf og fremgangsmåder til humanisering af antistofpeptider |
| EP1213030B1 (en) | 1994-11-10 | 2009-04-22 | Baxter Healthcare SA | Method for producing biologicals in protein-free culture |
| AU703484B2 (en) | 1995-02-23 | 1999-03-25 | Quest International Services B.V. | Peptides for tissue and cell culture media |
| AUPN442295A0 (en) | 1995-07-26 | 1995-08-17 | Commonwealth Scientific And Industrial Research Organisation | Regulated autocrine growth of mammalian cells |
| CU22584A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis |
| AT407255B (de) * | 1997-06-20 | 2001-02-26 | Immuno Ag | Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons |
-
2002
- 2002-10-23 CU CU20020239A patent/CU23097A1/es unknown
-
2003
- 2003-10-10 PE PE2003001035A patent/PE20040552A1/es not_active Application Discontinuation
- 2003-10-16 AR ARP030103776A patent/AR041645A1/es active IP Right Grant
- 2003-10-17 MY MYPI20033959A patent/MY144088A/en unknown
- 2003-10-22 DK DK03757654.3T patent/DK1564285T3/da active
- 2003-10-22 BR BRPI0315565A patent/BR0315565B1/pt active IP Right Grant
- 2003-10-22 ES ES03757654T patent/ES2360049T3/es not_active Expired - Lifetime
- 2003-10-22 US US10/532,269 patent/US20060036082A1/en not_active Abandoned
- 2003-10-22 CA CA2503315A patent/CA2503315C/en not_active Expired - Lifetime
- 2003-10-22 NZ NZ540171A patent/NZ540171A/en not_active IP Right Cessation
- 2003-10-22 WO PCT/CU2003/000012 patent/WO2004038010A1/es not_active Ceased
- 2003-10-22 KR KR1020057006995A patent/KR101186048B1/ko not_active Expired - Lifetime
- 2003-10-22 PT PT03757654T patent/PT1564285E/pt unknown
- 2003-10-22 EA EA200500695A patent/EA007465B1/ru not_active IP Right Cessation
- 2003-10-22 JP JP2004545689A patent/JP4674087B2/ja not_active Expired - Lifetime
- 2003-10-22 CN CN2003801036918A patent/CN1714147B/zh not_active Expired - Lifetime
- 2003-10-22 AT AT03757654T patent/ATE502103T1/de active
- 2003-10-22 EP EP11155076.0A patent/EP2363418B1/en not_active Expired - Lifetime
- 2003-10-22 EP EP03757654A patent/EP1564285B1/en not_active Expired - Lifetime
- 2003-10-22 GE GEAP20038815A patent/GEP20084444B/en unknown
- 2003-10-22 AU AU2003273727A patent/AU2003273727B2/en not_active Expired
- 2003-10-22 DE DE60336415T patent/DE60336415D1/de not_active Expired - Lifetime
- 2003-10-22 HR HR20050760A patent/HRP20050760A2/xx not_active Application Discontinuation
- 2003-10-22 ES ES11155076.0T patent/ES2624279T3/es not_active Expired - Lifetime
- 2003-10-23 UY UY28037A patent/UY28037A1/es not_active Application Discontinuation
-
2005
- 2005-04-22 TN TNP2005000116A patent/TNSN05116A1/en unknown
- 2005-04-22 EC EC2005005740A patent/ECSP055740A/es unknown
- 2005-05-19 LT LT2005053A patent/LT5354B/lt not_active IP Right Cessation
- 2005-05-23 LV LVP-05-61A patent/LV13361B/en unknown
-
2010
- 2010-04-13 US US12/759,208 patent/US20100197011A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019232477A3 (en) | Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies | |
| DE69521794D1 (de) | Zellen mit mehreren geänderten epitopen auf einem oberflächeantigen zur verwendung in transplantation | |
| CY1110695T1 (el) | Μεθοδοι για την δημιουργια υψηλου τιτλου ανευ-βοηθου παρασκευασματων απελευθερωμενων ανασυνδυασμενων aav φορεων | |
| MX2009014273A (es) | Metodos y composiciones para expansion e implantacion optimizadas de celulas madre mesenquimales. | |
| ATE324030T1 (de) | Brassica-transformation durch teilchenbeschuss | |
| MX2019010575A (es) | Metodo para producir anticuerpos multiespecificos. | |
| MX2020009907A (es) | Glicoformas afucosiladas totales de anticuerpos producidos en cultivo celular. | |
| MX2025004565A (es) | Anticuerpos anti-cd3 dependientes de ph y metodos relacionados con estos | |
| MX2025005078A (es) | Composiciones que contienen enzimas que escinden anticuerpos y metodos de uso de las mismas. | |
| Li et al. | In vivo dedifferentiation of human epidermal cells | |
| AR041645A1 (es) | Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo | |
| EP4234686A3 (en) | Transduction and expansion of cells | |
| EP4269595A3 (en) | Methods for selectively expanding cells expressing a tcr with a murine constant region | |
| ATE494377T1 (de) | Vakzine gegen ipnv die aus hefezellen isoliert werden | |
| AR126198A1 (es) | Procesamiento de linfocitos infiltrantes de tumores | |
| ATE322540T1 (de) | Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender | |
| MX2023007302A (es) | Anticuerpos contra la integrina alfa 11 beta 1. | |
| WO2004092345A3 (en) | Transformation of brassica | |
| MXPA02010471A (es) | Metodo para la obtencion de lineas celulares en medio libre de proteina y lineas celulares obtenidas por este metodo. | |
| BRPI0518449A2 (pt) | mÉtodos para produzir cÉlulas mamÍferas | |
| MX2021011375A (es) | Cultivos de linfocitos t cd28, composiciones y métodos para su uso. | |
| MX2023007028A (es) | Composiciones de proteínas y métodos para producir y usar las mismas. | |
| BRPI0409383A (pt) | métodos para produção livre de hibridoma ex vivo de anticorpos policlonais e monoclonais e geração de populações de célula imortalizada | |
| Trung et al. | Study on some properties of the hybrid cell B4D10C9 producing the anti B monoclonal antibody which was agglutinated the b antigens on the surface of red blood cells | |
| Martinkaitytė et al. | Stem Cell Therapy in Multiple Sclerosis: Current Progress and Future Prospects. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |